Blue Cross of Idaho Logo

Express Sign-on

Thank you for registering with Blue Cross of Idaho

If you are an Individual or Family Member, please register here.

If you are a Medicare Advantage or Medicare Supplement member, please register here.

MP 8.01.21 Allogeneic Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Medical Policy    
Original Policy Date
Last Review Status/Date
Reviewed with literature search/11:2014
  Return to Medical Policy Index


Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract.  Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage.  Medical technology is constantly changing, and we reserve the right to review and update our policies periodically. 



Hematopoietic Stem-Cell Transplantation

Hematopoietic stem cells may be obtained from the transplant recipient (autologous HSCT) or from a donor (allogeneic HSCT). They can be harvested from bone marrow, peripheral blood, or umbilical cord blood shortly after delivery of neonates. Although cord blood is an allogeneic source, the stem cells in it are antigenically “naïve” and thus are associated with a lower incidence of rejection or graft-versus-host disease (GVHD). Cord blood is discussed in greater detail in policy No. 7.01.50.

Immunologic compatibility between infused hematopoietic stem cells and the recipient is not an issue in autologous HSCT. However, immunologic compatibility between donor and patient is a critical factor for achieving a good outcome of allogeneic HSCT. Compatibility is established by typing of human leukocyte antigens (HLA) using cellular, serologic, or molecular techniques. HLA refers to the tissue type expressed at the HLA-A, B, and DR loci on each arm of chromosome 6. Depending on the disease being treated, an acceptable donor will match the patient at all or most of the HLA loci.

Conventional Preparative Conditioning for HSCT

The conventional (“classical”) practice of allogeneic HSCT involves administration of cytotoxic agents (eg, cyclophosphamide, busulfan) with or without total-body irradiation at doses sufficient to destroy endogenous hematopoietic capability in the recipient. The beneficial treatment effect in this procedure is due to a combination of initial eradication of malignant cells and subsequent graft-versus-malignancy (GVM) effect that develops after engraftment of allogeneic stem cells within the patient’s bone marrow space. While the slower GVM effect is considered to be the potentially curative component, it may be overwhelmed by extant disease without the use of pretransplant conditioning. However, intense conditioning regimens are limited to patients who are sufficiently fit medically to tolerate substantial adverse effects that include preengraftment opportunistic infections secondary to loss of endogenous bone marrow function and organ damage and failure caused by the cytotoxic drugs. Furthermore, in any allogeneic HSCT, immune suppressant drugs are required to minimize graft rejection and GVHD, which also increases susceptibility of the patient to opportunistic infections.

Reduced-Intensity Conditioning for Allogeneic HSCT

Reduced-intensity conditioning (RIC) refers to the pretransplant use of lower doses or less intense regimens of cytotoxic drugs or radiation than are used in conventional full-dose myeloablative (MA) conditioning treatments. The goal of RIC is to reduce disease burden but also to minimize as much as possible associated treatment-related morbidity and nonrelapse mortality (NRM) in the period during which the beneficial GVM effect of allogeneic transplantation develops. Although the definition of RIC remains arbitrary, with numerous versions employed, all seek to balance the competing effects of NRM and relapse due to residual disease. RIC regimens can be viewed as a continuum in effects, from nearly totally MA to minimally MA with lymphoablation, with intensity tailored to specific diseases and patient condition. Patients who undergo RIC with allogeneic HSCT initially demonstrate donor cell engraftment and bone marrow mixed chimerism. Most will subsequently convert to full-donor chimerism, which may be supplemented with donor lymphocyte infusions to eradicate residual malignant cells. For the purposes of this Policy, the term “reduced-intensity conditioning” will refer to all conditioning regimens intended to be nonmyeloablative, as opposed to fully MA (conventional) regimens.

Myelodysplastic Syndromes

Myelodysplastic syndromes (MDS) can occur as a primary (idiopathic) disease or can be secondary to cytotoxic therapy, ionizing radiation, or other environmental insult. Chromosomal abnormalities are seen in 40–60% of patients, frequently involving deletions of chromosome 5 or 7, or an extra chromosome as in trisomy 8. Signs and symptoms of anemia, often complicated by infections or bleeding, are common in MDS; some patients exhibit systemic symptoms or features of autoimmunity that may be indicative of their disease pathogenesis. The vast majority of MDS diagnoses occur in individuals older than age 55–60 years, with an age-adjusted incidence of approximately 62% among individuals older than age 70 years. Patients either succumb to disease progression to acute myelocytic leukemia (AML) or to complications of pancytopenias. Patients with higher blast counts or complex cytogenetic abnormalities have a greater likelihood of progressing to AML than do other patients.

MDS Classification and Prognosis

For the past 20 years, the French-American-British (FAB) system has been used to classify MDS into 5 subtypes as follows: (1) refractory anemia (RA); (2) refractory anemia with ringed sideroblasts (RARS); (3) refractory anemia with excess blasts (RAEB); (4) refractory anemia with excess blasts in transformation (RAEBT); and, (5) chronic myelomonocytic leukemia (CMML). However, the FAB system has been supplanted by that of the World Health Organization (WHO), which records the number of lineages in which dysplasia is seen (unilineage vs. multilineage), separates the 5q-syndrome, and reduces the threshold maximum blast percentage for the diagnosis of MDS from 30% to 20% (see Policy Guidelines for WHO classification scheme for myeloid neoplasms).

The most commonly used prognostic scoring system for MDS is the International Prognostic Scoring System (IPSS), which groups patients into 1 of 4 prognostic categories based on the number of cytopenias, cytogenetic profile, and the percentage of blasts in the bone marrow (see Policy Guidelines section). This system underweights the clinical importance of severe, life-threatening neutropenia and thrombocytopenia in therapeutic decisions and does not account for the rate of change in critical parameters, such as peripheral blood counts or blast percentage. However, the IPSS has been useful in comparative analysis of clinical trial results and its utility confirmed at many institutions. A second prognostic scoring system incorporates the WHO subgroup classification that accounts for blast percentage, cytogenetics, and severity of cytopenias as assessed by transfusion requirements. The WHO Classification-based Prognostic Scoring System (WPSS) uses a 6-category system, which allows more precise prognostication of overall survival (OS) duration, as well as risk for progression to AML. This system, however, is not yet in widespread use in clinical trials.

MDS Treatment

Treatment of smoldering or nonprogressing MDS has in the past involved best supportive care including red blood cell (RBC) and platelet transfusions and antibiotics. Active therapy was given only when MDS progressed to AML or resembled AML with severe cytopenias. A diverse array of therapies are now available to treat MDS, including hematopoietic growth factors (eg, erythropoietin, darbepoetin, granulocyte colony-stimulating factor), transcriptional-modifying therapy (eg, U.S. Food and Drug Administration [FDA]‒approved hypomethylating agents, nonapproved histone deacetylase inhibitors), immunomodulators (eg, lenalidomide, thalidomide, antithymocyte globulin, cyclosporine A), low-dose chemotherapy (eg, cytarabine), and allogeneic HSCT. Given the spectrum of treatments available, the goal of therapy must be decided upfront, whether it is to improve anemia; thrombocytopenia; or neutropenia, eliminate the need for red blood cell transfusion, achieve complete remission, or cure the disease.

Allogeneic HSCT is the only approach with curative potential, but its use is governed by patient age, performance status, medical comorbidities, the patient’s risk preference, and severity of MDS at presentation.

Chronic Myeloproliferative Neoplasms

Overview of Chronic Myeloproliferative Neoplasms

Chronic MPNs are clonal bone marrow stem-cell disorders; as a group, an approximate total of 8400 MPNs are diagnosed annually in the United States. Like MDS, MPNs primarily occur in older individuals, with approximately 67% reported in patients aged 60 years and older.

MPNs are characterized by the slow but relentless expansion of a clone of cells with the potential evolution into a blast crisis similar to AML. They share a common stem cell-derived clonal heritage, with phenotypic diversity attributed to abnormal variations in signal transduction as the result of a spectrum of mutations that affect protein tyrosine kinases or related molecules. The unifying characteristic common to all MPNs is effective clonal myeloproliferation resulting in peripheral granulocytosis, thrombocytosis, or erythrocytosis that is devoid of dyserythropoiesis, granulocytic dysplasia, or monocytosis.

MPN Classification

In 2008, a new WHO classification scheme replaced the term chronic myeloproliferative disorder with the term MPNs. These are a subdivision of myeloid neoplasms that includes the 4 classic disorders: chronic myeloid leukemia, polycythemia vera, essential thrombocytopenia, and primary myelofibrosis; the WHO classification also includes chronic neutrophilic leukemia, chronic eosinophilic leukemia/hypereosinophilic
syndrome, mast cell disease, and MPNs unclassifiable (see Policy Guidelines section).

MPN Treatment

In indolent, nonprogressing cases, therapeutic approaches are based on relief of symptoms. Supportive therapy may include prevention of thromboembolic events. Hydroxyurea may be used in cases of highrisk essential thrombocytosis and polycythemia vera and intermediate- and high-risk primary myelofibrosis.

In November 2011, FDA approved the orally administered selective Janus kinase 1 and 2 inhibitor ruxolitinib for the treatment of intermediate- or high-risk myelofibrosis. Ruxolitinib has been associated with improved OS, spleen size, and symptoms of myelofibrosis when compared with placebo.(1) The COMFORT-II trial compared ruxolitinib to best available therapy in patients with intermediate- and highrisk
myelofibrosis, and demonstrated improvements in spleen volume and OS.(2) In a randomized trial comparing ruxolitinib with best available therapy, including antineoplastic agents, most commonly hydroxyurea, glucocorticoids, and no therapy, for myelofibrosis, Harrison et al demonstrated improvements in spleen size and quality of life, but not OS.(3)

MA allogeneic HSCT has been considered the only potentially curative therapy, but because most patients are of advanced age with attendant comorbidities, its use is limited to those who can tolerate the often severe treatment-related adverse effects of this procedure. However, the use of RIC of conditioning regimens for allogeneic HSCT has extended the potential benefits of this procedure to selected individuals with these disorders.



Myeloablative allogeneic HSCT may be considered medically necessary as a treatment of

  • myelodysplastic syndromes (see Policy Guidelines) or
  • myeloproliferative neoplasms (see Policy Guidelines).

Reduced-intensity conditioning allogeneic HSCT may be considered medically necessary as a treatment of

  • myelodysplastic syndromes or
  • myeloproliferative neoplasms

in patients who for medical reasons would be unable to tolerate a myeloablative conditioning regimen. (see Policy Guidelines)

Myeloablative allogeneic HSCT or reduced-intensity conditioning allogeneic HSCT for myelodysplastic syndromes and myeloproliferative neoplasms that does not meet the criteria in the Policy Guidelines is considered investigational.

Policy Guidelines


The myeloid neoplasms are categorized according to criteria developed by the World Health Organization. They are risk-stratified according to the International Prognostic Scoring System (IPSS).

2008 WHO Classification Scheme for Myeloid Neoplasms

  1. Acute myeloid leukemia
  2. Myelodysplastic syndromes (MDS)
  3. Myeloproliferative neoplasms (MPN)
    • 3.1 Chronic myelogenous leukemia
    • 3.2 Polycythemia vera
    • 3.3 Essential thrombocythemia
    • 3.4 Primary myelofibrosis
    • 3.5 Chronic neutrophilic leukemia
    • 3.6 Chronic eosinophilic leukemia, not otherwise categorized
    • 3.7 Hypereosinophilic leukemia
    • 3.8 Mast cell disease
    • 3.9 MPNs, unclassifiable
  4. MDS/MPN
    • 4.1 Chronic myelomonocytic leukemia
    • 4.2 Juvenile myelomonocytic leukemia
    • 4.3 Atypical chronic myeloid leukemia
    • 4.4 MDS/MPN, unclassifiable
  5. Myeloid neoplasms associated with eosinophilia and abnormalities of PDGFRA, PDGFRB, or FGFR1
    • 5.1 Myeloid neoplasms associate with PDGFRA rearrangement
    • 5.2 Myeloid neoplasms associate with PDGFRB rearrangement
    • 5.3 Myeloid neoplasms associate with FGFR1 rearrangement (8p11 myeloproliferative syndrome)

2008 WHO Classification of MDS

  1. Refractory anemia (RA)
  2. RA with ring sideroblasts (RARS)
  3. Refractory cytopenia with multilineage dysplasia (RCMD)
  4. RCMD with ring sideroblasts
  5. RA with excess blasts 1 and 2 (RAEB 1 and 2)
  6. del 5q syndrome
  7. unclassified MDS

Risk Stratification of MDS

Risk stratification for MDS is performed using the IPSS. This system was developed after pooling data from 7 previous studies that used independent, risk-based prognostic factors. The prognostic model and the scoring system were built based on blast count, degree of cytopenia, and blast percentage. Risk scores were weighted relative to their statistical power. This system is widely used to divide patients into 2 categories: (1) low-risk and (2) high-risk groups. The low-risk group includes low-risk and Int-1 IPSS groups; the goals in low-risk MDS patients are to improve quality of life and achieve transfusion independence. In the high-risk group—which includes Int-2 and high-risk IPSS groups— the goals are slowing the progression of disease to AML and improving survival. The IPSS is usually calculated on diagnosis. The role of lactate dehydrogenase, marrow fibrosis, and beta 2-microglobulin also should be considered after establishing the IPSS. If elevated, the prognostic category becomes worse by one category change.

IPSS: MDS Prognostic Variables

Variable  0   0.5   1.0   1.5   2.0  
Marrow blasts (%)  <5   5-10   -   11-20   21-30  
Karyotype  Good   Intermediate   Poor      
Cytopenias  0/1   2/3   -   -   -  

IPSS: MDS Clinical Outcomes

Risk Group  Total Score  Median Survival, yrs  Time for 25% to Progress to AML, yrs 
Low   0   5.7   9.4  
Intermediate-1   0.5-1.0   3.5   3.3  
Intermediate-2   1.5-2.0   1.2   1.12  
High   2.5 or more   0.4   0.2  

Given the long natural history of MDS, allogeneic HSCT is typically considered in those with increasing numbers of blasts, signaling a possible transformation to acute myeloid leukemia. Subtypes falling into this category include refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or chronic myelomonocytic leukemia.

Patients with refractory anemia with or without ringed sideroblasts may be considered candidates for allogeneic HSCT when chromosomal abnormalities are present or the disorder is associated with the development of significant cytopenias (e.g., neutrophils less 500/mm3, platelets less than 20,000/mm3).

Patients with MPNs may be considered candidates for allogeneic HSCT when there is progression to myelofibrosis or when there is evolution toward acute leukemia. In addition, allogeneic HSCT may be considered in patients with essential thrombocythemia with an associated thrombotic or hemorrhagic disorder. There are no suitable U.S. Food and Drug Administration (FDA) -approved therapies for these patients, only supportive care. The use of allogeneic HSCT should be based on cytopenias, transfusion dependence, increasing blast percentage over 5%, and age.

Some patients for whom a conventional myeloablative allogeneic HSCT could be curative may be considered candidates for RIC allogeneic HSCT. These include those patients whose age (typically older than 60 years) or comorbidities (e.g., liver or kidney dysfunction, generalized debilitation, prior intensive chemotherapy, low Karnofsky Performance Status) preclude use of a standard myeloablative conditioning regimen. The ideal allogeneic donors are HLA-identical siblings, matched at the HLA-A, B, and DR loci (6 of 6). Related donors mismatched at 1 locus are also considered suitable donors. A matched, unrelated donor (MUD) identified through the National Marrow Donor Registry is typically the next option considered. Recently, there has been interest in haploidentical donors, typically a parent or a child of the patient, where usually there is sharing of only 3 of the 6 major histocompatibility antigens. The majority of patients will have such a donor; however, the risk of GVHD and overall morbidity of the procedure may be severe, and experience with these donors is not as extensive as that with matched donors.

Clinical input suggests RIC allogeneic HSCT may be considered for patients as follows:


  • IPSS intermediate-2 or high risk
  • RBC transfusion dependence
  • Neutropenia
  • Thrombocytopenia
  • High-risk cytogenetics
  • Increasing blast percentage


  • Cytopenias
  • Transfusion dependence
  • Increasing blast percentage over 5%
  • Age 60-65 years


Benefit Application
BlueCard/National Account Issues


No applicable information.


This policy was originally created in December 1999 and updated periodically with literature reviews, most recently through September 30, 2014. Following is the summary of the key literature to date. 

Myelodysplastic Syndromes

Conventional Preparative Conditioning Hematopoietic Stem-Cell Transplantation for Myelodysplastic Syndromes

Despite the successes seen with new drugs now available to treat myelodysplastic syndromes (MDS; eg, decitabine, azacitidine, lenalidomide), allogeneic hematopoietic stem-cell transplantation (HSCT) is the only treatment capable of complete and permanent eradication of the myelodysplastic syndrome (MDS) clone.(4)

A 2009 review of HSCT for MDS evaluated the evidence for allogeneic HSCT with myeloablative (MA) conditioning for MDS.(5) The authors included 24 studies (prospective and retrospective) published between 2000 and 2008 that included a total 1378 cases with an age range of 32 to 59 years. Most patients (n=885) received matched-related donor allogeneic HSCT, with other donor types including syngeneic, matched, unrelated donor, mismatched unrelated donor, and umbilical cord blood. Most studies included de novo and secondary MDS, chronic myelomonocytic leukemia (CML), MPNs, de novo and secondary acute myelocytic leukemia (AML), and transformed AML. Peripheral blood and bone marrow stem-cell grafts were allowed in most studies. The most commonly used conditioning regimens were busulfan plus cyclophosphamide (BU/CY) and CY plus total body irradiation (CY/TBI), with cyclosporine A (CYA) used for graft-versus-host disease (GVHD) prophylaxis. Length of follow-up ranged from 5 months to approximately 8 years. Grades II to IV acute GVHD varied from 18% to 100%. Relapse risk ranged from a low of 24% at 1 year to 36% at 5 years. Overall survival (OS) ranged from 25% at 2 years to 52% at 4 years, with nonrelapse mortality (NRM) ranging from 19% at day 100 to 61% at 5 years.

A review from the American Society for Blood and Marrow Transplantation (ASBMT) in 2009 assembled and evaluated the evidence related to HSCT in the therapy of MDS, with associated treatment recommendations.(6) The authors conclude that outcomes are improved with early HSCT for patients with an International Prognostic Scoring System (IPSS) score of intermediate-2 or high-risk at diagnosis, who have a suitable donor, and meet the transplant center’s eligibility criteria, and for selected patients with a low or intermediate-1 risk IPSS score at diagnosis who have a poor prognostic feature not included in the IPSS (ie, older age, refractory cytopenias)
Reduced Intensity Conditioning HSCT for MDS Evidence from a number of largely heterogeneous, uncontrolled studies of reduced-intensity conditioning (RIC) with allogeneic HSCT shows long-term remissions (ie, >4 years) can be achieved, often with reduced treatment-related morbidity and mortality, in patients with MDS/AML who otherwise would not be candidates for MA conditioning regimens.(7-18) These prospective and retrospective studies included cohorts of 16 to 215 patients similar to those in the MA allogeneic HSCT studies. The most common conditioning regimens used were fludarabine-based, with CYA and tacrolimus used for GVHD prophylaxis. The reported incidence of grades II to IV GVHD was 9% to 63%, with relapse risk of 6% to 61%. The OS rates ranged between 44% at 1 year to 46% at 5 years, with a median follow-up range of 14 months to over 4 years.

In 2013, Kim et al published a randomized phase 3 trial to compare the toxicities of 2 different conditioning regimens (reduced cyclophosphamide [Cy], fludarabine, and antithymocyte globulin [ATG]; standard Cy-ATG).(19) Four (of 83) patients had MDS, and the remaining study patients had severe aplastic anemia. Overall, the incidence of toxicities were reported to be lower in patients receiving the reducedconditioning regimen (23% vs 55%; p=0.003). Subgroup analyses showed no differences in the overall results based on differential diagnosis.(19)

In general, these RIC trials showed a low rate of engraftment failure and low NRM but at the cost of a higher relapse rate than with MA allogeneic HSCT. However, in the absence of prospective, comparative, randomized trials, only indirect comparisons can be made between the relative clinical benefits and harms associated with MA and RIC regimens with allogeneic HSCT. Furthermore, no randomized trials have been published in which RIC with allogeneic HSCT has been compared with conventional
chemotherapy alone, which has been the standard of care in patients with MDS/AML for whom MA chemotherapy and allogeneic HSCT are contraindicated. Nonetheless, given the absence of curative therapies for these patients, coupled with clinical input (see next), RIC allogeneic HSCT may be considered medically necessary for patients with MDS who could benefit from allogeneic HSCT but who for medical reasons (see Policy Guidelines section) would be unable to tolerate a MA conditioning regimen.

The 2009 ASBMT systematic review previously described addressed the evidence to support RIC compared with MA conditioning regimens and makes the following conclusions, “There are insufficient data to make a recommendation for an optimal conditioning regimen intensity. A range of dose intensities is currently being investigated, and the optimal approach will likely depend on disease and patient characteristics, such as age and comorbidities.”

Other recent reviews concur with the ASBMT recommendations.(20-25)

Smaller studies continue to report outcomes from HSCT for MDS in variety of patient populations and to evaluate the impact of specific patient, conditioning, and donor characteristics on outcomes; representative studies are summarized in Table 3.

Table 3: Case Series of HSCT Treatment for MDS


Patient Population

Type of HSCT

Summary of Outcomes


et al


52 pediatric patients with MDS

·         Allo-HSCT

·         59% with related  donors

·         Stem-cell source:

·         Bone marrow, 63%

·         Peripheral blood, 26%

·         Umbilical cord blood, 11%

·         5-y DFS: 50%

·         5-y OS: 55%

Boehm et al


60 adults with MDS or secondary AML

·         Allo-HSCT

·         MA conditioning in 36 patients; RIC conditioning in 24

10-y OS: 46%

Damaj et al


128 adults with MDS, 40 of whom received AZA before HSCT and 88 who received BSC


·         3-y OS: 53% for AZA group vs 53% for BSC group (p=0.69)

·         3-y RFS: 37% for AZA group vs 42% for BSC group (p=0.78)

·         3-y NRM: 20% for AZA group vs 23% for BSC group (p=0.74)

Di Stasi et

al (2014)(29)

227 patients with MDS or AML

·         Allo-HSCT.

·         Donor source:

o   Matched-related donor, 38%

o   Matched-unrelated donor, 48%

o   Haploidentical, 14%

3-y PFS for patients in remission:

·         57% for matched-related donor

·         45% for matched-unrelated donor

·         41% for haploidentical (p=0.417)

Onida et al


·         523 patients with MDS treated with HSCT

·         IPSS cytogenic risk group:

o   Good risk: 53.5%

o   Intermediate risk: 24.5%

o   Poor risk: 22%

o   Allo-HSCT

o   RIC conditioning in 12%

5-y OS based on IPSS cytogenic

risk group:

o   Good risk: 48%

o   Intermediate risk: 45%

o   Poor risk: 30%

Oran et al


·         256 patients with MDS

·         Pretreatment:

o   No cytoreductive chemotherapy: 30.5%

o   Chemotherapy: 15.6%

o   HMA: 47.7%

o   Chemo + HMA: 6.2%

·         Allo-HSCT

·         RIC conditioning in 36.7%

3-y EFS based on cytoreductive therapy:

·         No cytoreductive chemotherapy: 44.2%

·         Chemotherapy: 30.6%

·         HMA: 34.2%

·         Chemo + HMA: 32.8% (p=0.50)

Yoshimi et

al (2014)(32)

17 children with secondary MDS/AML after childhood aplastic anemia


5-y OS and EFS: 41%

AML: acute myelogenous leukemia; AZA: azacitidine; BSC: best supportive care; DFS: disease-free survival; HMA: hypomethylating agents; HSCT: hematopoietic stem-cell transplantation; IPSS: International Prognostic Scoring System; MA: myeloablative; MDS: myelodysplastic syndrome; NRM: nonrelapse mortality; OS: overall survival; RIC: reduced-intensity conditioning; RFS: relapse-free survival.

Myeloproliferative Neoplasms

Data on therapy for MPN remain sparse.(15,33,34) As outlined previously in this policy, with the exception of MA chemotherapy and allogeneic HSCT, no therapy has yet been proven to be curative or to prolong survival of patients with MPN.

However, the significant toxicity of MA conditioning and allogeneic HSCT in MPN has led to study of RIC regimens for these diseases. One recent series included 27 patients (mean age, 59 years) with MPN who underwent allogeneic HSCT using an RIC regimen of low-dose (2 Gy) total body irradiation alone or with the addition of fludarabine.(13) At a median follow-up of 47 months, the 3-year relapse-free survival was 37%, and OS was 43%, with a 3-year NRM of 32%. In a second series, 103 patients (median age, 55 years; range, 32-68 years) with intermediate to high risk (86% of total patients) primary myelofibrosis or postessential thrombocythemia and polycythemia vera myelofibrosis were included on a prospective multicenter phase 2 trial to determine efficacy of a busulfan plus fludarabine-based RIC regimen followed
by allogeneic HSCT from related (n=33) or unrelated (n=70) donors.(35) Acute grade II-IV GVHD occurred in 27%, and chronic GVHD in 43% of patients. The cumulative incidence of NRM at 1 year in all patients was 16% (95% confidence interval [CI], 9% to 23%) but reached 38% (95% CI, 15% to 61%) among those with a mismatched donor versus 12% (95% CI, 5% to 19%) among cases with a matched donor (p=0.003). The cumulative relapse rate at 3 and 5 years was 22% (95% CI, 13% to 31%) and 29% (95% CI, 16% to 42%), respectively. After a median follow-up of 33 months (range, 12-76 months) 5-year estimated disease-free survival (DFS) and OS was 51% (95% CI, 38% to 64%) and 67% (95% CI, 55% to 79%), respectively.

The largest study of allogeneic HSCT for primary myelofibrosis comes from analysis of the outcomes of 289 patients treated between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR).(36) The median age was 47 years (range, 18-73 years). Donors were HLA-identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and GVHD prophylaxis regimens. Splenectomy was performed in 65 patients before transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year OS rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival in about one-third of patients.

Gupta et al reported better DFS rates in a more recent analysis of 233 patients with primary myelofibrosis who underwent RIC HSCT from 1997 to 2010.37 Five-year OS was 47% (95% CI, 40% to 53%). Conditioning regimen was not significantly associated with OS.

Data from direct, prospective comparison of outcomes of MA conditioning and allogeneic HSCT versus RIC and allogeneic stem-cell support in MPN are not available. However, a recent retrospective study analyzed the impact of conditioning intensity on outcomes of allogeneic HSCT in patients with myelofibrosis (MF).(38) This multicenter trial included 46 consecutive patients treated at 3 Canadian and 4 European transplant centers between 1998 and 2005. Twenty-three patients (median age, 47 years; range, 31-60 years) underwent MA conditioning, and 23 patients (median age, 54 years; range, 38-74 years) underwent RIC. The majority in both groups (85%) were deemed intermediate- or high-risk. At a median follow-up of 50 months (range, 20-89), there was a trend for better progression-free survival at 3 years in RIC patients compared with MA-conditioned patients (58%; range, 23-62 vs 43%; range, 35-76, respectively; p=0.11); there was a similar trend in 3-year OS (68%; range, 45-84 vs 48%; range, 27-66, respectively; p=0.08). NRM rates at 3 years trended higher in MA-conditioned cases than RIC cases (48%; range, 31-74 vs 27%; range, 14-55, respectively; p=0.08). The results of this study suggest that both types of conditioning regimens have curative potential in patients with MF. Despite the RIC patients being significantly older with longer disease duration and poorer performance status than those who received conventional conditioning, the groups had similar outcomes, supporting the use of RIC allogeneic HSCT in this population.

In a retrospective study in 9 Nordic transplant centers, a total of 92 patients with myelofibrosis in chronic phase underwent allogeneic HSCT.(39) MA conditioning was given to 40 patients, and RIC was used in 52 patients. The mean age in the 2 groups at transplantation was 46±12 and 55±8 years, respectively (p<0.001). When adjustment for age differences was made, the survival of the patients treated with RIC was significantly better (p=0.003). Among the RIC patients, survival was significantly (p=0.003) greater for patients younger than age 60 years (a 10-year survival close to 80%) than for patients older than 60 years. The stem-cell source did not significantly affect the survival. No significant difference was found in NRM at 100 days between the MA- and the RIC-treated patients. The probability of survival at 5 years was 49% for the MA-treated patients and 59% in the RIC group (p=0.125). Patients treated with RIC experienced significantly less acute GVHD compared with patients treated with MA conditioning (p<0.001). The OS at 5 years was 70%, 59% and 41% for patients with Lille score 0, 1 and 2, respectively (p=0.038, when age adjustment was made). Twenty-one percent of the patients in the RIC group were given donor lymphocyte infusion because of incomplete donor chimerism, compared with none of the MA treated patients (p<0.002). Nine percent of the patients needed a second transplant because of graft failure, progressive disease or transformation to AML, with no significant difference between the groups.

Ongoing and Unpublished Clinical Trials

A search of in October 2014 identified the following phase 3 trials of hematopoietic stem-cell transplant for MDS.

  • Stem Cell Transplant for Hematological Malignancy (NCT00176930) – This is a nonrandomized efficacy study to evaluate allogeneic transplant after conditioning with cyclophosphamide and total body irradiation or cyclophosphamide and busulfan for multiple types of hematologic malignancies, including MDS and myeloproliferative disease. The primary outcome is progression-free survival. Enrollment is planned for 350 patients; the estimated study completion date is December 2016.
  • Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies (NCT00619879) – This is a nonrandomized, safety/efficacy study to evaluate hematopoietic progenitor-cell transplantation following myeloablative conditioning in children with hematologic malignancies, including  myelodysplastic/myeloproliferative disease (primarily juvenile myelomonocytic leukemia and MDS and preleukemia at any stage). Enrollment is planned for 200 patients; the estimated study completion date is January 2020.
  • Randomized Allogeneic Azacitidine Study (NCT00887068) – This is a randomized, safety/efficacy study to compare post-transplant azacitidine following HSCT for AML or MDS. Enrollment is planned for 246 patients; the estimated study completion date is April 2016.
  • PRO#1278: Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation (NCT01366612) – This is a randomized, safety/efficacy study to compare the addition of total body irradiation with fludarabine and busulfan for preconditioning for allogeneic stem-cell transplant for patients with AML, chronic myelogenous leukemia, other myeloproliferative disorder, or MDS. The primary outcome is relapse rate at 1 year posttransplant. Enrollment is planned for 54 patients; the estimated study completion date is December 2014.
  • Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) (NCT01471444) – This is a randomized, safety/efficacy study to compare fludarabine-clofarabine and busulfan with fludarabine alone with busulfan for conditioning for patients with the following disorders: AML, at any stage and cytogenetic risk-group with the only exception being that patients with AML and favorable cytogenetics who achieve complete remission with 1 course of induction chemotherapy are not eligible; MDSs with intermediate- or high-risk IPSS scores or treatment-related MDS.  Patients with low-risk MDS are eligible if they fail to respond to hypomethylating agent therapy such as azacitidine or decitabine. Enrollment is planned for 250 subjects; the estimated study completion date is November 2016.

Clinical Input Received From Physician Specialty Societies and Academic Medical Centers

In response to requests, input was received from 2 academic medical center specialists prior to review for May 2009. While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

There was consensus among reviewers that RIC allogeneic HSCT was of value in patients with MDS or MPN who would be medically unable to tolerate an MA HSCT.

Summary of Evidence

Hematopoietic stem-cell transplantation (HSCT) is at present the only potentially curative treatment option for patients with myelodysplastic syndromes and myeloproliferative neoplasms. The absence of other curative therapies coupled with clinical data and input permit the conclusion that allogeneic HSCT using either a myeloablative or reduced-intensity conditioning regimen is medically necessary in appropriately selected patients with these conditions. Patient selection is guided by age and disease risk factors, as outlined in the Policy Guidelines section.

Practice Guidelines and Position Statements

National Comprehensive Cancer Network Guidelines

The 2015 National Comprehensive Cancer Network (NCCN) clinical practice guidelines for myelodysplastic syndromes (v.1.2015)(40) makes the following recommendation regarding HSCT in general: “For patients who are transplant candidates, the first choice of a donor has remained an HLAmatched sibling, although results with HLA-matched unrelated donors have improved to levels comparable to those obtained with HLA-matched siblings. With the increasing use of cord blood or HLAhaploidentical
related donors, HSCT has become a viable option for many patients. High-dose conditioning is typically used for younger patients, whereas RIC for HSCT is generally the strategy in older individuals.”

Specific NCCN guidelines related to HSCT for MDS are outlined in Table 4.

Table 4: NCCN Guidelines for HSCT for MDS

Prognostic Category

Recommendation for HSCT

IPSS low/intermediate-1 OR
IPSS-R very low, low, intermediate OR
WPSS very low, low, intermediate OR

  • Consider allogeneic HSCT for selected IPSS-1 patients who have clinically relevant thrombocytopenia or neutropenia or increased marrow blasts, with disease progression after azacitidine/decitabine or immunosuppressive therapy for selected patients or clinical trial
  • Consider allogeneic HSCT for selected IPSS-1 patients who have symptomatic anemia with no 5q deletion, with serum erythropoietin level >500 mU/mL, with poor probability of response to immunosuppressive therapy, and no response or intolerance to azacitidine/decitabine or immunosuppressive therapy for selected patients or clinical trial

IPSS intermediate-2, high OR
IPSS-R intermediate, high, very high OR
WPSS high, very high

Recommend allogeneic HSCT if a high-intensity therapy candidate and transplant candidate and donor available

HSCT: hematopoietic stem-cell transplantation; IPSS: International Prognostic Scoring System; NCCN: National Comprehensive Cancer Network; WPSS: WHO Classification-based Prognostic Scoring System.

U.S. Preventive Services Task Force Recommendations
Not applicable.

Medicare National Coverage
There is no national coverage determination (NCD). In the absence of an NCD, coverage decisions are left to the discretion of local Medicare carriers. 


  1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. Mar 1 2012;366(9):799-807. PMID 22375971
  2. Cervantes F, Vannucchi AM, Kiladjian JJ, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood. Dec 12 2013;122(25):4047-4053. PMID 24174625
  3. Harrison C, Kiladjian J-J, Al-Ali HK, et al. JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis. N Engl J Med. 2012;366(9):787-798. PMID 22375970
  4. Kasner MT, Luger SM. Update on the therapy for myelodysplastic syndrome. Am J Hematol. 2009;84(3):177- 186.
  5. Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant. Apr 2009;43(8):597-609. PMID 19252532
  6. Oliansky DM, Antin JH, Bennett JM, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review. Biol Blood Marrow Transplant. 2009;15(2):137-172.
  7. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol. 2008;45(1):49-59.
  8. Blaise D, Vey N, Faucher C, et al. Current status of reduced-intensity-conditioning allogeneic stem cell transplantation for acute myeloid leukemia. Haematologica. 2007;92(4):533-541.
  9. Deschler B, de Witte T, Mertelsmann R, et al. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica. 2006;91(11):1513-1522.
  10. Huisman C, Meijer E, Petersen EJ, et al. Hematopoietic stem cell transplantation after reduced intensity conditioning in acute myelogenous leukemia patients older than 40 years. Biol Blood Marrow Transplant. 2008;14(2):181-186.
  11. Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant. 2009;43(8):597-609.
  12. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine/busulfanbased reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003;82(6):336-342.
  13. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14(2):246-55.
  14. Martino R, Caballero MD, Perez-Simon JA, et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood. 2002;100(6):2243-2245.
  15. Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program. 2007:355-362. PMID 18024651
  16. Tauro S, Craddock C, Peggs K, et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol. 2005;23(36):9387-9393.
  17. Valcarcel D, Martino R. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia. Curr Opin Oncol. 2007;19(6):660-666.
  18. Valcarcel D, Martino R, Caballero D, et al. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival. J Clin Oncol. 2008;26(4):577-584.
  19. Kim H, Lee JH, Joo YD, et al. A randomized comparison of cyclophosphamide vs. reduced dose cyclophosphamide plus fludarabine for allogeneic hematopoietic cell transplantation in patients with aplastic anemia and hypoplastic myelodysplastic syndrome. Ann Hematol. Sep 2012;91(9):1459-1469. PMID 22526363
  20. Akhtari M. When to treat myelodysplastic syndromes. Oncology (Williston Park). 2011;25(6):480-486.
  21. Deeg HJ, Sandmaier BM. Who is fit for allogeneic transplantation? Blood. Dec 2 2010;116(23):4762-4770. PMID 20702782
  22. Giralt SA, Horowitz M, Weisdorf D, et al. Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. J Clin Oncol. 2011;29(5):566-572.
  23. Deeg HJ, Bartenstein M. Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: current status. Arch Immunol Ther Exp (Warsz). Feb 2012;60(1):31-41. PMID 22143157
  24. Garcia-Manero G. Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol. Jul 2012;87(7):692-701. PMID 22696212
  25. Kroger N. Allogeneic stem cell transplantation for elderly patients with myelodysplastic syndrome. Blood. Jun 14 2012;119(24):5632-5639. PMID 22504927
  26. Basquiera AL, Pizzi S, Correas AG, et al. Allogeneic hematopoietic stem cell transplantation in pediatric myelodysplastic syndromes: A multicenter experience from Argentina. Pediatr Blood Cancer. Sep 27 2014. PMID 25264233
  27. Boehm A, Sperr WR, Kalhs P, et al. Long-term follow-up after allogeneic stem cell transplantation in patients with myelodysplastic syndromes or secondary acute myeloid leukemia: a single center experience. Wien Klin Wochenschr. Jan 2014;126(1-2):23-29. PMID 24249320
  28. Damaj G, Mohty M, Robin M, et al. Upfront allogeneic stem cell transplantation after reducedintensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire. Biol Blood Marrow Transplant. Sep 2014;20(9):1349-1355. PMID 24838178
  29.  Di Stasi A, Milton DR, Poon LM, et al. Similar Transplant Outcomes for AML/MDS Patients with Haploidentical versus 10/10 HLA Matched Unrelated and Related Donors. Biol Blood Marrow Transplant. Sep 24 2014. PMID 25263628
  30. Onida F, Brand R, van Biezen A, et al. Impact of the International Prognostic Scoring System cytogenetic risk groups on the outcome of patients with primary myelodysplastic syndromes undergoing allogeneic stem cell transplantation from Human Leukocyte Antigen-identical siblings: a retrospective analysis of the European Society for Blood and Marrow Transplantation-Chronic Malignancies Working Party. Haematologica. Aug 1 2014. PMID 25085359
  31. Oran B, Kongtim P, Popat U, et al. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant. Oct 2014;20(10):1618-1625. PMID 24953017
  32. Yoshimi A, Strahm B, Baumann I, et al. Hematopoietic stem cell transplantation in children and young adults with secondary myelodysplastic syndrome and acute myelogenous leukemia after aplastic anemia. Biol Blood Marrow Transplant. Mar 2014;20(3):425-429. PMID 24316460
  33. Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011;29(5):573-582.
  34. McLornan DP, Mead AJ, Jackson G, et al. Allogeneic stem cell transplantation for myelofibrosis in 2012. Br J Haematol. May 2012;157(4):413-425. PMID 22463701
  35. Kroger N, Holler E, Kobbe G, et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood. 2009;114(26):5264-5270.
  36. Ballen KK, Shrestha S, Sobocinski KA, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358-367.
  37. Gupta V, Malone AK, Hari PN, et al. Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant. Jan 2014;20(1):89-97. PMID 24161923
  38. Gupta V, Kroger N, Aschan J, et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant. 2009;44(5):317-320.
  39. Abelsson J, Merup M, Birgegard G, et al. The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries. Bone Marrow Transplant. Mar 2012;47(3):380-386. PMID 21552298
  40. (NCCN) NCCN. Myelodysplastic Syndromes v1.2015. 2014; Accessed October 1, 2014.





CPT  38204 Management of recipient hematopoietic cell donor search and cell acquisition
  38205 Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection, allogeneic
  38208 Transplant preparation of hematopoietic progenitor cells; thawing of previously frozen harvest
  38209 ;thawing of previously frozen harvest with washing
  38210 ;specific cell depletion with harvest,T cell depletion

;tumor cell depletion

  38212 ;red blood cell removal
  38213 ;platelet depletion
  38214 ;plasma (colume) depletion
  38215 ;cell concentration in plasma, mononuclear, or buffy coat layer
  38230  Bone marrow harvesting for transplantation  
  38240  Bone marrow or blood-derived peripheral stem-cell transplantation: allogeneic 
  86812-86822 Histocompatibility studies code range
(e.g., for allogeneic transplant) 
ICD-9 Procedure  41.02  Allogeneic bone marrow transplant with purging 
  41.03  Allogeneic bone marrow transplant without purging 
  41.05  Allogeneic hematopoietic stem-cell transplant 
  41.08 Allogeneic hematopoietic stem-cell transplant with purging
  41.91  Aspiration of bone marrow from donor for transplant 
  99.79  Other therapeutic apheresis (includes harvest of stem cells) 
ICD-9 Diagnosis  238.7-238.79 Myelofibrosis or myelodysplastic syndrome, code range (myeloproliferative syndrome is included in 238.79)
HCPCS  S2150 Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, allogeneic or autologous, including pheresis, high-dose chemotherapy, and the number of days of post-transplant care in the global definition (including drugs; hospitalization; medical surgical, diagnostic and emergency services)
ICD-10-CM (effective 10/1/15) C92.10 – C92.12 Chronic myeloid leukemia, BCR/ABL-positive code range
  C92.20 – C92.22 Atypical chronic myeloid leukemia, BCR/ABL-negative code range
  C94.6 Myelodysplastic disease, not classified Myeloproliferative disease, not classified
  D45 Polycythemia vera
  D46.0-D46.9 Myelodysplastic syndromes code range
  D47.0 – D47.9 Other neoplasms of uncertain behavior of lymphoid, hematopoietic and related tissue code range
ICD-10-PCS (effective 10/1/15)   ICD-10-PCS codes are only used for inpatient services.
  30243G1, 30243X1, 30243Y1 Percutaneous transfusion, central vein, bone marrow or stem cells, nonautologous, code list
  07DQ0ZZ, 07DQ3ZZ, 07DR0ZZ, 07DR3ZZ, 07DS0ZZ, 07DS3ZZ Surgical, lymphatic and hemic systems, extraction, bone marrow, code list
Type of Service  Therapy 
Place of Service  Inpatient/Outpatient 

High-dose Chemotherapy, Myelodysplastic Syndrome
High-dose Chemotherapy, Myeloproliferative Syndrome
Myelodysplastic Syndrome, High-dose Chemotherapy
Stem-Cell Transplant, Myelodysplastic Diseases

Policy History





Add to Therapy section

New policy; policy represents revision of policy No.7.03.10 to focus on myelodysplasia and myelofibrosis. New policy statement on high-dose chemotherapy for myelofibrosis


Replace policy

Policy updated without literature review; new review date only


Replace policy

Policy updated with literature review; policy statement also includes mini-transplant. References added, cross-referenced to policy No. 8.01.38 on mini-transplants


Replace policy

Policy updated with literature review; no change in policy statement. No further scheduled review

04/17/07 Replace policy Policy updated with literature review. References 6 and 9–11 added. No change in policy statement; policy scheduled for annual review. Code table updated.
05/08/08 Replace policy  Policy updated with literature review; reference 11 updated; references 12-18 added. No change in policy statements. “Myeloproliferative” Diseases added to policy title.
06/12/08 Replace policy Policy updated with literature review; reference 11 updated; references 12-18 added. Minor terminology changes to policy statements; however, the intent of the policy statements remains unchanged. “Myeloproliferative” Diseases added to policy title’ “High-Dose Chemotherapy” removed from title.
06/11/09 Replace policy Policy completely rewritten with literature review and input from external clinical vetting. References 1 and 2 added, outdated references deleted. Term “Myeloproliferative Disorders” replaced with “Myeloproliferative Neoplasms” in title and text. Policy statements revised to indicate that RIC HSCT may be considered medically necessary as a treatment of myelodysplastic syndrome and myeloproliferative neoplasms in patients who for medical reasons would be unable to tolerate a myeloablative conditioning regimen.
11/11/10 Replace policy Policy updated with literature search, reference numbers 14-17 added, policy statement unchanged.
11/10/11 Replace policy Policy updated with literature search; references 15-18 and 20 added. Policy statements unchanged.
11/08/12 Replace Policy Policy updated with literature search; reference 26 added. Policy statements unchanged.
11/14/13 Replace policy Policy updated with literature search through October 8, 2013; reference 14 added. Policy statements unchanged.
11/13/14 Replace policy Policy updated with literature review through September 30, 2014. References 1-3, 5-6, 26-32, and 37 added. Policy statements unchanged.

Resource Center

Find a Provider Find a Pharmacy Medicare Medicare Formulary